News
ARAY
0.5286
-4.74%
-0.0263
Accuray Delays Quarterly Filing After Disclosure Review
TipRanks · 1d ago
Accuray Delays Quarterly Financial Report Filing
Reuters · 1d ago
Accuray meldet Verzögerung bei Finanzberichterstattung
Reuters · 1d ago
ACCURAY INC - 2025 FINANCIAL STATEMENTS SHOULD NO LONGER BE RELIED UPON - SEC FILING
Reuters · 1d ago
ACCURAY: IDENTIFIED MATERIAL WEAKNESSES RELATED TO REVIEW OF FOOTNOTE SCHEDULES SUPPORTING FINANCIAL STATEMENT DISCLOSURES
Reuters · 1d ago
ACCURAY: ERRORS EXPECTED TO HAVE NO IMPACT ON BALANCE SHEETS, INCOME STATEMENTS INCLUDED IN PREVIOUSLY FILED ANNUAL/ INTERIM FINANCIAL STATEMENTS
Reuters · 1d ago
Weekly Report: what happened at ARAY last week (0202-0206)?
Weekly Report · 2d ago
Accuray Receives Nasdaq Notice Over Minimum Bid Price
TipRanks · 4d ago
Accuray Receives Nasdaq Noncompliance Notice, Gets Time Through Aug. 3 To Regain Compliance
Benzinga · 4d ago
The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Simply Wall St · 5d ago
Groundhog Day Once Again, As Accuray Misses And Lowers
Seeking Alpha · 5d ago
Accuray Earnings Call: Tough Quarter, Focused Turnaround
TipRanks · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
Accuray price target lowered to $2 from $4 at BTIG
TipRanks · 6d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 6d ago
Accuray resets 2026 outlook to $440M–$450M revenue and $22M–$25M adjusted EBITDA amid transformation plan
Seeking Alpha · 6d ago
Accuray (ARAY) Q2 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Accuray Posts Weaker Q2 Results Amid Ongoing Transformation
TipRanks · 6d ago
Accuray GAAP EPS of -$0.11 beats by $0.01, revenue of $102.2M beats by $1.34M
Seeking Alpha · 6d ago
More
Webull provides a variety of real-time ARAY stock news. You can receive the latest news about Accuray Incorp through multiple platforms. This information may help you make smarter investment decisions.
About ARAY
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.